Australian stem cell therapy company, Mesoblast Limited (ASX:MSB) revealed Phase 2/3 trial outcomes of remestemcel-L and mentioned that 83% (10/12) survival in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during the period March-April 2020.
Moreover, 75% (9/12) have successfully come off ventilator support within a median of 10 days.
The patients were treated with two infusions of remestemcel-L within the first five days.
Post announcement the share price of MSB skyrocketed by 24.173% to $2.440 (at AEST 11:33 AM).
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.